[1] Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. J Hepatol, 2014,61:642-659.
[2] Blei AT, Córdoba J. Hepatic Encephalopathy. Am J Gastroenterol,2001,96:1968-1976.
[3] Rockey DC, Vierling JM, Mantry P, et al. Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology,2014,59:1073-1083.
[4] Hassanein T, Blei AT, Perry W, et al. Performance of the hepatic encephalopathy scoring algorithm in a clinical trial of patients with cirrhosis and severe hepatic encephalopathy. Am J Gastroenterol,2009,104:1392-1400.
[5] Drolz A, J?ger B, Wewalka M, et al. Clinical impact of arterial ammonia levels in ICU patients with different liver diseases. Intensive Care Med,2013,39(7):1227-1237.
[6] Shalimar, Sheikh MF, Mookerjee RP, et al. Prognostic Role of Ammonia in Patients With Cirrhosis. Hepatology,2019,70:982-994.
[7] Bajaj JS, Lauridsen M, Tapper EB, et al. Important Unresolved Questions in the Management of Hepatic Encephalopathy: An ISHEN Consensus. Am J Gastroenterol,2020,115:989-1002.
[8] Bossen L, Ginès P, Vilstrup H, et al. Serum sodium as a risk factor for hepatic encephalopathy in patients with cirrhosis and ascites. J Gastroenterol Hepatol,2019,34:914-20.
[9] Watson H, Guevara M, Vilstrup H, et al. Improvement of hyponatremia in cirrhosis is associated with improved complex information processing. J Gastroenterol Hepatol,2019,34:1999-2003.
[10] McMillin M, Frampton G, Grant S, et al. Bile Acid-Mediated Sphingosine-1-Phosphate Receptor 2 Signaling Promotes Neuroinflammation during Hepatic Encephalopathy in Mice. Front Cell Neurosci,2017,11:191.
[11] Hadjihambi A, Harrison IF, Costas-Rodríguez M, et al. Impaired brain glymphatic flow in experimental hepatic encephalopathy. J Hepatol, 2019,70:40-49.
[12] Butterworth RF. Neurosteroids in hepatic encephalopathy: Novel insights and new therapeutic opportunities. J Steroid Biochem Mol Biol, 2016,160:94-97.
[13] Weiss N, Barbier Saint Hilaire P, Colsch B, et al. Cerebrospinal fluid metabolomics highlights dysregulation of energy metabolism in overt hepatic encephalopathy. J Hepatol, 2016,65:1120-1130.
[14] García-Lezana T, Oria M, Romero-Giménez J, et al. Cerebellar neurodegeneration in a new rat model of episodic hepatic encephalopathy. J Cereb Blood Flow Metab,2017,37:927-937.
[15] Aceto P, Perilli V, Lai C, et al. Postoperative cognitive dysfunction after liver transplantation. Gen Hosp Psychiatry,2015,37:109-115.
[16] Görg B, Karababa A, H?ussinger D. Hepatic Encephalopathy and Astrocyte Senescence. J Clin Exp Hepatol,2018,8:294-300.
[17] Davis BC, Bajaj JS. The Human Gut Microbiome in Liver Diseases. Semin Liver Dis,2017,37:128-140.
[18] Nava GM, Stappenbeck TS. Diversity of the autochthonous colonic microbiota. Gut Microbes,2011,2:99-104.
[19] Tranah TH, Vijay GK, Ryan JM, et al. Systemic inflammation and ammonia in hepatic encephalopathy. Metab Brain Dis,2013,28:1-5.
[20] Chen Y, Yang F, Lu H, et al. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology,2011,54:562-572.
[21] Qin N, Yang F, Li A, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature,2014,513:59-64.
[22] Bajaj JS, Heuman DM, Hylemon PB, et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol, 2014,60:940-947.
[23] Chen Y, Ji F, Guo J, et al. Dysbiosis of small intestinal microbiota in liver cirrhosis and its association with etiology. Sci Rep, 2016,6:34055.
[24] Bajaj JS, Betrapally NS, Hylemon PB, et al. Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy. Hepatology, 2015,62:1260-1271.
[25] Santiago A, Pozuelo M, Poca M, et al. Alteration of the serum microbiome composition in cirrhotic patients with ascites. Sci Rep,2016,6:25001.
[26] Bajaj JS, Liu EJ, Kheradman R, et al. Fungal dysbiosis in cirrhosis. Gut, 2018,67:1146-1154.
[27] Bhanji RA, Moctezuma-Velazquez C, Duarte-Rojo A, et al. Myosteatosis and sarcopenia are associated with hepatic encephalopathy in patients with cirrhosis. Hepatol Int,2018,12:377-386.
[28] Weiss N, Thabut D. Neurological Complications Occurring After Liver Transplantation: Role of Risk Factors, Hepatic Encephalopathy, and Acute (on Chronic) Brain Injury. Liver Transpl,2019,25:469-487.
[29] Campagna F, Montagnese S, Schiff S, et al. Cognitive impairment and electroencephalographic alterations before and after liver transplantation: what is reversible? Liver Transpl,2014,20:977-986.
[30] Weiss N, Tripon S, Lodey M, et al. Treating hepatic encephalopathy in cirrhotic patients admitted to ICU with sodium phenylbutyrate: a preliminary study. Fundam Clin Pharmacol,2018,32:209-15.
[31] Bajaj JS, Kassam Z, Fagan A, et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial. Hepatology,2017,66:1727-1738.
[32] Kurtz CB, Millet YA, Puurunen MK, et al. An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans. Sci Transl Med,2019,11:eaau7975.
[33] Agostoni V, Lee SH, Forster V, et al. Liposome‐Supported Peritoneal Dialysis for the Treatment of Hyperammonemia‐Associated Encephalopathy. Advanced Functional Materials,2016.
[34] Bosoi CR, Parent-Robitaille C, Anderson K, et al. AST-120 (spherical carbon adsorbent) lowers ammonia levels and attenuates brain edema in bile duct-ligated rats. Hepatology,2011,53:1995-2002.
[35] Agusti A, Llansola M, Hernández-Rabaza V, et al. Modulation of GABAA receptors by neurosteroids. A new concept to improve cognitive and motor alterations in hepatic encephalopathy. J Steroid Biochem Mol Biol,2016,160:88-93.
[36] Song G, Kerbert A, Jones H, et al. Recombinant glutamine synthetase: a novel strategy for the treatment of hyperammonemia and consequent hepatic encephalopathy in rodent model of cirrhosis and urea cycle enzyme deficiency. J Hepatol,2019,70:e93-e94. |
